Explore

Trendline Trendline
Amylyx Pharmaceuticals to Present at Needham Virtual Healthcare Conference

Amylyx Pharmaceuticals to Present at Needham Virtual Healthcare Conference

Amylyx Pharmaceuticals to Present at Needham Virtual Healthcare Conference
Trendline Trendline
Neurocrine Biosciences Acquires Soleno Therapeutics in $2.9 Billion Deal, Expanding Rare Disease Portfolio

Neurocrine Biosciences Acquires Soleno Therapeutics in $2.9 Billion Deal, Expanding Rare Disease Portfolio

Neurocrine Biosciences Acquires Soleno Therapeutics in $2.9 Billion Deal, Expanding Rare Disease Portfolio
Trendline Trendline
Cingulate's ADHD Drug Faces FDA Manufacturing Review, No Safety Concerns Reported

Cingulate's ADHD Drug Faces FDA Manufacturing Review, No Safety Concerns Reported

Cingulate's ADHD Drug Faces FDA Manufacturing Review, No Safety Concerns Reported
Trendline Trendline
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion
Trendline Trendline
Stonegate Capital Partners Updates Coverage on Cingulate Inc. Amid Manufacturing Focus

Stonegate Capital Partners Updates Coverage on Cingulate Inc. Amid Manufacturing Focus

Stonegate Capital Partners Updates Coverage on Cingulate Inc. Amid Manufacturing Focus
Trendline Trendline
Apnimed Secures $150 Million Financing for Sleep Apnea Treatment Launch

Apnimed Secures $150 Million Financing for Sleep Apnea Treatment Launch

Apnimed Secures $150 Million Financing for Sleep Apnea Treatment Launch
Trendline Trendline
Allucent Expands Leadership to Enhance Drug Development for Biopharma

Allucent Expands Leadership to Enhance Drug Development for Biopharma

Allucent Expands Leadership to Enhance Drug Development for Biopharma
Trendline Trendline
Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities
Trendline Trendline
Amphastar Pharmaceuticals to Present at Needham Healthcare Conference Highlighting Strategic Growth

Amphastar Pharmaceuticals to Present at Needham Healthcare Conference Highlighting Strategic Growth

Amphastar Pharmaceuticals to Present at Needham Healthcare Conference Highlighting Strategic Growth
Trendline Trendline
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding into Metabolic Disorders

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding into Metabolic Disorders

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding into Metabolic Disorders
Trendline Trendline
Rosen Law Firm Files Class Action Against Aldeyra Therapeutics Over Misleading Statements

Rosen Law Firm Files Class Action Against Aldeyra Therapeutics Over Misleading Statements

Rosen Law Firm Files Class Action Against Aldeyra Therapeutics Over Misleading Statements
Trendline Trendline
Vyome to Present Phase 2 Clinical Data on VT-1953 for Malignant Fungating Wounds at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for Malignant Fungating Wounds at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for Malignant Fungating Wounds at AACR 2026